Higher visceral adipose tissue correlated with lower rates of inflammatory bowel disease remission among patients dosed with infliximab, vedolizumab or ustekinumab, according to Andres Yarur, MD, Medical College of Wisconsin.
“A significant amount of patients with Crohn’s disease or ulcerative colitis experience partial or non-response to biologic therapy. This is explained by several things, some of them we know, some of them we do not,” Yarur said. “Identifying the variables that are associated with partial and non-response is important to improve the prognosis of our patients.”
Full Article: https://www.healio.com/news/gastroenterology/20210910/video-increased-visceral-adipose-tissue-links-to-decreased-ibd-remission